AstraZeneca gets positive feedback on possible Imfinzi indication
26th Jul 2024 09:15
(Sharecast News) - AstraZeneca's 'Imfinzi', or durvalumab, was recognised by the FDA's oncologic drugs advisory committee (ODAC) on Friday for its efficacy in treating resectable non-small cell lung cancer (NSCLC), based on phase three trial results.
Read moreLondon close: Stocks mixed on tsunami of updates, US GDP data
25th Jul 2024 15:27
(Sharecast News) - London stocks closed with mixed results on Thursday as investors processed faster-than-anticipated economic growth in the United States, following a heavy flow of corporate announcements earlier in the day.
Read moreAstraZeneca hikes full-year guidance after strong first half
25th Jul 2024 07:19
(Sharecast News) - AstraZeneca revised its full-year 2024 guidance upwards on Thursday, anticipating mid-teens percentage growth in both total revenue and core earnings per share at constant exchange rates.
Read moreAstraZeneca endometrial cancer treatment recommended for EU approval
1st Jul 2024 07:17
(Sharecast News) - AstraZeneca announced on Monday that 'Imfinzi', or durvalumab, and 'Lynparza', or olaparib, have received a recommendation for approval in the European Union (EU) as treatments for primary advanced or recurrent endometrial cancer in patients with specific genetic profiles.
Read moreAstraZeneca posts mixed results from recent Imfinzi trials
25th Jun 2024 07:17
(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.
Read moreAstraZeneca trial fails to treat 'challenging' breast cancer
18th Jun 2024 07:17
(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.
Read moreAstraZeneca's Imfinzi gets US approval for endometrial cancer patients
17th Jun 2024 07:15
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
Read moreLondon pre-open: Stocks set for lower start after EU elections
10th Jun 2024 06:25
(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.
Read moreAstraZeneca's lung cancer treatment recommended for approval in EU
3rd Jun 2024 07:28
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
Read moreAstraZeneca experimental lung cancer drug shows promising results
28th May 2024 07:02
(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.
Read moreSector movers: Stocks slip amid light profit-taking
21st May 2024 19:00
(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.
Read moreLondon close: Stocks fall ahead of key inflation reading
21st May 2024 15:00
(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.
Read moreAstraZeneca lays out plans to hit $80bn in revenues by 2030
21st May 2024 07:34
(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.
Read moreAstraZeneca announces $1.5bn Singapore manufacturing facility
20th May 2024 07:22
(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).
Read moreSector movers: Aerospace and Defence, Pharma pace gains
8th May 2024 19:10
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.
Read more